SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated | Psychiatric Times
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. AnxietyMental HealthResearchDosingSafetyNeurologyIndustry Why This Matters Clinicians treating generalized anxiety…
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AnxietyMental HealthNeurologyResearchSafetyIndustrySleep Why This Matters Clinicians treating generalized anxiety…
Cannabis Dosing in Family Medicine: Evidence-Based Care for Endocannabinoid System Regulation
CBD dominant edibles anxiety relief shows significant promise in reducing anxiety symptoms. Cannabis dosing for anxiety varies by product type and cannabinoid composition. This evidence-based approach supports family medicine care focused on…
Experiences with Marijuana and OCD: Patient Perspectives
Cannabis OCD symptom relief is a topic of growing interest among patients and clinicians. Some report meaningful symptom relief, while others note potential worsening of compulsive behaviors. This discussion highlights the complexity of cannabis use in…
Medicinal Cannabis Doesn’t Help Anxiety, Depression, or PTSD, Huge Review Finds
A large systematic review found limited evidence for cannabis in treating mental health disorders such as anxiety, depression, and PTSD. This challenges the widespread use of medicinal cannabis for these psychiatric conditions. Clinicians should…
Anxiety and Depression: Shocking 1.83X Suicide Risk – Wigmore on Alcohol
Anxiety depression suicide risk is significantly elevated with comorbid substance use, increasing clinical complexity. This 1.83-fold risk highlights the importance of careful cannabis prescribing decisions. Clinicians must monitor patients closely to…
Cannabis Withdrawal and Anxiety Disorder Have Identical Symptoms. One of Them Has a …
Cannabis withdrawal syndrome presents symptoms that closely resemble anxiety disorders, complicating diagnosis. Understanding cannabis withdrawal syndrome is essential for proper treatment decisions. Misdiagnosis can lead to ineffective or unnecessary…
In the Mix: 9 More Articles — March 30, 2026
This article reviews cannabis products policy and regulation amid evolving 2026 wellness markets. It highlights the clinical evidence gap and consumer misinformation challenges. Clinicians must navigate these complexities carefully.
Study Finds No Benefit of Psychedelic Therapy Over Antidepressants
The psychedelic therapy antidepressants study reveals no significant benefit of psychedelic therapy compared to antidepressants. This research highlights the need for careful evaluation of treatment options for depression. Understanding these findings…
Exploring the Relationship Between Cannabis, Depression, and Anxiety
This article examines cannabis and mood disorders, focusing on depression and anxiety. The evidence reveals a complex relationship where cannabis may relieve or worsen symptoms. Understanding cannabis and mood disorders is essential for clinical guidance.
